Veterans study reveals Real-World patterns of prostate cancer drug use
NCT ID NCT06462014
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study analyzed medical records of 507 U.S. veterans with prostate cancer who started taking the drug relugolix between 2020 and 2023. Researchers wanted to understand the patients' backgrounds, previous treatments, and health conditions. The study did not test a new treatment but instead gathered information to see how relugolix is being used in everyday practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?